<div id="readability-page-1"><p>FreeGulliver LLC purchased a new stake in  MDxHealth SA (NASDAQ:MDXH - Free Report) in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor  purchased 123,546 shares of the company's stock, valued at approximately $273,000. FreeGulliver LLC owned about 0.26% of MDxHealth at the end of the most recent quarter.</p><p>Separately, AWM Investment Company Inc. lifted its stake in  MDxHealth by 10.6% during the first quarter. AWM Investment Company Inc. now owns 5,221,282 shares of the company's stock valued at $7,414,000 after purchasing an additional 499,992 shares during the last quarter. </p><h2>MDxHealth Price Performance</h2><p>NASDAQ MDXH opened at $3.57 on Tuesday. The company has a debt-to-equity ratio of 13.81, a current ratio of 1.31 and a quick ratio of 1.22. The firm has a market capitalization of $168.82 million, a price-to-earnings ratio of -4.06 and a beta of 1.68. The company has a 50 day simple moving average of $4.28 and a 200-day simple moving average of $3.14. MDxHealth SA has a 52-week low of $1.35 and a 52-week high of $5.33. </p><p>MDxHealth (NASDAQ:MDXH - Get Free Report) last released its earnings results on Wednesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.04). MDxHealth had a negative return on equity of 374.98% and a negative net margin of 34.98%.The company had revenue of $27.43 million during the quarter, compared to analysts' expectations of $24.11 million.  MDxHealth has set its FY 2025 guidance at  EPS. Equities research analysts predict that  MDxHealth SA will post -1.15 earnings per share for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of brokerages recently issued reports on MDXH. Wall Street Zen upgraded MDxHealth to a &#34;hold&#34; rating in a report on Saturday, August 30th. Weiss Ratings  restated a &#34;sell (e+)&#34; rating on shares of MDxHealth in a report on Wednesday, October 8th. TD Cowen lifted their target price on shares of MDxHealth from $5.00 to $7.00 and gave the stock a &#34;buy&#34; rating in a research report on Thursday, November 13th. BTIG Research boosted their price target on shares of MDxHealth from $6.00 to $7.00 and gave the company a &#34;buy&#34; rating in a report on Thursday, November 13th. Finally, Lake Street Capital raised their price objective on shares of MDxHealth from $7.00 to $9.00 and gave the stock a &#34;buy&#34; rating in a research note on Thursday, November 13th. Four analysts have rated the stock with a Buy rating and one  has given a Sell rating to the company. Based on data from MarketBeat, MDxHealth presently has an average rating of &#34;Moderate Buy&#34; and a consensus price target of $7.75.</p><p><b>Read Our Latest Stock Analysis on MDXH</b></p><h2>About MDxHealth</h2> (Free Report)<p>MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its testing solutions includes Select mdx, a non-invasive urine test for prostate cancer that measures the expression of two mRNA cancer-related biomarkers; Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient's previously biopsied negative tissue; and Resolved mdx for urinary tract infection that identifies personalized effective antibiotic options against the patient's infection.</p><h2>Read More</h2><ul><li>Five stocks we like better than MDxHealth</li><li>Stock Sentiment Analysis: How it Works</li><li>5 Retail Stocks That Could Deck the Halls—or Wreck Portfolios</li><li>REIT Stocks - Best REIT Stocks to Add to Your Portfolio Today</li><li>D-Wave: Time to Buy the Dip? Or is the Fall Just Starting?</li><li>Ride Out The Recession With These Dividend Kings </li><li>Hims, Block, and NRG Just Launched Huge Stock Buybacks </li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TURYSA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in MDxHealth Right Now?</h2><p>Before you consider MDxHealth, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and MDxHealth wasn't on the list.</p><p>While MDxHealth currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

MDXH

<p>FreeGulliver LLC acquired 123,546 shares of MDxHealth SA, valued at approximately $273,000, as per their latest SEC filing. This purchase represents about 0.26% ownership in MDxHealth. The company's stock performance and financial metrics were also discussed, including a recent earnings report and analyst ratings. MDxHealth has a Moderate Buy rating with a consensus price target of $7.75. The company specializes in precision diagnostics for urologic solutions.</p>

123,546 Shares in MDxHealth SA $MDXH Purchased by FreeGulliver LLC